Identifying factors in platinum resistance for ovarian cancer
Platino-resistance in Ovarian Cancer
NA · Institut Claudius Regaud · NCT03954171
This study is trying to find out why some people with ovarian cancer don’t respond to standard platinum chemotherapy, by collecting information and samples from patients receiving this treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Institut Claudius Regaud (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT03954171 on ClinicalTrials.gov |
What this trial studies
This prospective study aims to identify factors contributing to resistance against platinum-based chemotherapy in patients diagnosed with epithelial ovarian cancer at any stage. Participants will receive standard platinum-based chemotherapy while clinical, biological, epidemiological, and therapeutic data will be collected over a five-year period. Biological samples, including blood, tumor biopsies, and ascites, will be collected concurrently with standard care procedures, ensuring no additional invasive procedures are required. The study will help build a comprehensive database to better understand treatment resistance.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with newly diagnosed epithelial ovarian cancer who are eligible for platinum-based chemotherapy.
Not a fit: Patients with non-epithelial ovarian tumors, recurrent disease, or those who have already undergone curative treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with platinum-resistant ovarian cancer.
How similar studies have performed: While studies on chemotherapy resistance exist, this specific approach focusing on platinum resistance in ovarian cancer is novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old 2. Epithelial ovarian cancer at initial diagnosis (all stages) 3. Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment 4. Indication of platinum based-chemotherapy 5. Patient affiliated to the french social security system 6. Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure Exclusion Criteria: 1. Non-epithelial ovarian tumor, borderline ovarian tumor 2. Patient with recurrent disease 3. Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)" 4. Pregnant or breastfeeding women 5. Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures 6. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Where this trial is running
Toulouse
- Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse, France (RECRUITING)
Study contacts
- Study coordinator: Gwenaël FERRON
- Email: Ferron.Gwenael@iuct-oncopole.fr
- Phone: 05 31 15 53 55
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Epithelial Ovarian Cancer, Platinum based-chemotherapy